Brief: Enveric Biosciences Announces Development Of Phase 1-Ready Formulation For EB-373 And Initiation Of Scaled Up Manufacturing
26/06/2023 13:20
June 26 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES ANNOUNCES DEVELOPMENT OF PHASE 1-READY
FORMULATION FOR EB-373 AND INITIATION OF SCALED UP MANUFACTURING
* ENVERIC BIOSCIENCES INC - TO EXPAND EXISTING MANUFACTURING
AGREEMENT WITH CDMO PARTNER FOR ENHANCED SUPPLY OF NON-GMP AND
GMP EB-373 DRUG SUBSTANCE
Source text for Eikon: ID:nBw9CRYwJa
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003